Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCALADARA: Daratumumab frequency escalation in relapsed/refractory multiple myeloma
NCT04150692Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2021
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Washington University School of Medicine. Planned start Jan 2021; status: withdrawn.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04150692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04150692.